Literature DB >> 28866071

Neuropathological and behavioral sequelae in IL-1R1 and IL-1Ra gene knockout mice after soman (GD) exposure.

Teresa M Ferrara-Bowens1, Jessica K Chandler2, Michelle A Guignet2, James F Irwin2, Kevin Laitipaya2, Devin D Palmer2, Lukas J Shumway2, Laura B Tucker3, Joseph T McCabe3, Matthew D Wegner2, Erik A Johnson2.   

Abstract

Soman (GD) exposure results in status epilepticus (SE) that leads to neurodegeneration, neuroinflammation, and behavioral consequences including learning and memory deficits. The neuroinflammatory response is characterized by the upregulation of the pro-inflammatory cytokine, interleukin-1 (IL-1), which mediates the expression of other neurotoxic cytokines induced after GD exposure. However, the specific role of IL-1 signaling has not been defined in terms of the consequences of GD-induced SE. Therefore, the purpose of this study was to regulate IL-1 signaling and study the behavioral deficits and neurodegeneration that occur after convulsion onset. Wild type (WT), IL-1 receptor (IL-1R1) knockout (KO), and IL-1 receptor antagonist (IL-1Ra) KO mice were exposed to a convulsive dose of GD, and behavior was evaluated up to 18days later. Activity was studied using the Open Field, anxiety was assessed in the Zero Maze, and spatial learning and memory were evaluated with the Barnes Maze. The animals were euthanized at 24hours and 18days to determine neuropathology in the piriform cortex, amygdala, thalamus, and CA1, CA2/3, and CA4 regions of the hippocampus. Unlike the IL-1Ra KO, the IL-1R1 KO showed less neuropathology compared to WT at 24hours, but moderate to severe injury was found in all strains at 18days. Compared to their saline controls, the exposed WT mice were significantly more active in the Open Field, and the IL-1R1 KO strain showed reduced anxiety in the Zero Maze Test. Compared to WT mice, IL-1R1 and IL-1Ra KO mice had spatial learning and memory impairments in the Barnes Maze. Therefore, the IL-1 signaling pathway affects neurodegeneration and behavior after GD-induced convulsions. Published by Elsevier B.V.

Entities:  

Keywords:  Behavior; Interleukin-1; Neurodegeneration; Neuroinflammation; Soman; Status epilepticus

Mesh:

Substances:

Year:  2017        PMID: 28866071     DOI: 10.1016/j.neuro.2017.08.010

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  5 in total

1.  TSPO PET Using [18F]PBR111 Reveals Persistent Neuroinflammation Following Acute Diisopropylfluorophosphate Intoxication in the Rat.

Authors:  Brad A Hobson; Douglas J Rowland; Sílvia Sisó; Michelle A Guignet; Zachary T Harmany; Suren B Bandara; Naomi Saito; Danielle J Harvey; Donald A Bruun; Joel R Garbow; Abhijit J Chaudhari; Pamela J Lein
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

Review 2.  Interleukin-1: an important target for perinatal neuroprotection?

Authors:  Sharmony B Kelly; Elys Green; Rod W Hunt; Claudia A Nold-Petry; Alistair J Gunn; Marcel F Nold; Robert Galinsky
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

Review 3.  Gut Microbes Regulate Innate Immunity and Epilepsy.

Authors:  Linhai Zhang; Shuang Li; Zhenzhen Tai; Changyin Yu; Zucai Xu
Journal:  Front Neurosci       Date:  2022-06-01       Impact factor: 5.152

4.  TRPV4 Regulates Soman-Induced Status Epilepticus and Secondary Brain Injury via NMDA Receptor and NLRP3 Inflammasome.

Authors:  Shuai Wang; Huanhuan He; Jianhai Long; Xin Sui; Jun Yang; Guodong Lin; Qian Wang; Yongan Wang; Yuan Luo
Journal:  Neurosci Bull       Date:  2021-03-24       Impact factor: 5.271

5.  Epicatechin Reduces Spatial Memory Deficit Caused by Amyloid-β25⁻35 Toxicity Modifying the Heat Shock Proteins in the CA1 Region in the Hippocampus of Rats.

Authors:  Alfonso Diaz; Samuel Treviño; Guadalupe Pulido-Fernandez; Estefanía Martínez-Muñoz; Nallely Cervantes; Blanca Espinosa; Karla Rojas; Francisca Pérez-Severiano; Sergio Montes; Moises Rubio-Osornio; Guevara Jorge
Journal:  Antioxidants (Basel)       Date:  2019-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.